ELLIOTT-ADVISORS-(UK)
19.7.2018 09:32:05 CEST | Business Wire | Press release
Funds advised by Elliott Advisors (UK) Limited (“Elliott”) are significant shareholders in thyssenkrupp AG (“thyssenkrupp” or the “Company”).
Elliott notes recent press coverage referencing the contents of a private letter Elliott sent to the thyssenkrupp Supervisory Board yesterday morning. In order to avoid any misunderstandings or misrepresentations of its substance, Elliott is hereby making the full text of the letter public.
***
The Members of the Supervisory Board
thyssenkrupp AG
thyssenkrupp Allee 1
45143 Essen
18 July 2018
Ladies and Gentlemen,
We note the resignation of Professor Dr. Ulrich Lehner as chairman of the Supervisory Board of thyssenkrupp AG.
When we met with Professor Lehner in Essen on 27th June he and we assured each other of our desire to develop a constructive working relationship. Professor Lehner’s comments in the interview he gave to Die Zeit on 12th July suggest that he did not give those assurances in good faith.
In the course of the interview with Die Zeit Professor Lehner gave his account of the current situation at thyssenkrupp and specifically singled out three shareholders: Krupp-Stiftung, Cevian and Elliott. Against this background, he denounced the behavior of certain ‘activist investors’ as ‘psycho-terror’ and accused them of ‘placing lies in public’, making ‘unjustified requests for resignations’, causing executives to seek ‘psychiatric counselling’ or even going as far as ‘harassing families and neighbours’, concluding that such shareholders are ‘not a benefit’ to the company. Any reasonable reader of this interview would have concluded that he was accusing Elliott of engaging in such behavior. To be clear, any such accusation is categorically untrue and is defamatory. As Professor Lehner could not have had any evidence for such accusations, we assume that he made them maliciously or, at least recklessly.
Our engagement with Professor Lehner and, before him, Dr Hiesinger in respect of thyssenkrupp cannot be described as anything other than the reasonable actions of a responsible, concerned and engaged investor. We have not at any stage, and contrary to Professor Lehner’s comments, demanded a dismantling (‘Zerschlagung’) of thyssenkrupp. Nevertheless, the company should continue to consider any structural evolution, such as the Steel JV, where such changes are determined to be in the interests of all stakeholders. You will be aware that, prior to our meeting with Professor Lehner, we had written to Dr Hiesinger on 24th May indicating our support for the Steel JV while at the same time pointing to analytical indicators that suggested better terms should be achievable in the negotiation. For that reason, we expected the Management Board to have negotiated a better transaction for the benefit of all stakeholders and the final outcome is therefore, from our point of view, very disappointing. The negotiated transaction relinquishes control over one of thyssenkrupp’s key legacy assets, and contributes it to a JV at a value considerably below that which could have been achieved. This view is shared by other investors and stakeholders, and arguably the board, given that the terms of the JV were ultimately amended, albeit insufficiently in our opinion.
We do not know if Professor Lehner’s resignation was required or requested by the Supervisory Board in response to his Die Zeit interview. We would expect that in circumstances where its chairman has made statements that untruthfully disparage shareholders the Supervisory Board would wish to take steps to remedy that situation. We therefore consider that it would be appropriate for the company and the Supervisory Board to distance itself from Professor Lehner’s defamatory remarks by publicly stating that the company does not support them and does not view them as truthful. To the extent the company is in a position to do so, it should take steps to ensure that Professor Lehner publicly withdraws these falsehoods and does not repeat them.
Notwithstanding these recent events, we hope that Professor Lehner’s resignation will now allow Elliott to establish the constructive working relationship with the new chairman and the Supervisory Board that we had hoped to build with him.
In that spirit, we look forward to the appointment of a new Chairman of
the Supervisory Board in the short term and we welcome the appointment
of Guido Kerkhoff as interim CEO, in that it provides some stability to
the group prior to the appointment of a new Chief Executive. However,
this interim period must be kept short so that thyssenkrupp may quickly
be set on a path to prosperity and growth. Shareholders expect an
unbiased search for a new external CEO, driven by what is best for the
company and all of its stakeholders, including shareholders.
Yours
faithfully,
Elliott Advisors (UK) Limited
About Elliott
Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005259/en/
Contact:
Media Contacts
London
Elliott
Advisors (UK) Limited
Sarah Rajani CFA, +44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Germany
Charles
Barker Corporate Communications
Thomas Katzensteiner / Tobias
Eberle, +49 69 79 40 90 25 / 24
Thomas.katzensteiner@charlesbarker.de
/ tobias.eberle@charlesbarker.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
